Últimas noticias sobre CytomX Therapeutics (NASDAQ:CTMX) Bolsa

CytomX Therapeutics

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

<p>Barclays  analyst Brandt Montour   maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Overweight and raises the price target from $40 to $44.</p>


News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Hilton Grand Vacations, Raises Price Target to $44

<p>Barclays  analyst David Anderson   maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Overweight and lowers the price target from $47 to $43.</p>


Barclays Maintains Overweight on Halliburton, Lowers Price Target to $43

Management

IMXI

Earlier Reported, International Money Express Believes That Current Market Valuation Does Not Fully Capture The Co's Performance, Positive Cash, Intrinsic Value Or Growth Potential. Committed To Acting In The Best Interest Of Shareholders, Initiating A Process To Assess Strategic Initiatives, Which Could Include Among Others, A Potential Sale In A Private Transaction

WIIM

Trump Media & Technology shares are trading higher following President-elect Donald Trump's election victory. Trump denied rumors of a potential share sale in a post on Truth Social.

<p>Barclays  analyst Saket Kalia   maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Equal-Weight and raises the price target from $85 to $95.</p>


FTNT

Barclays Maintains Equal-Weight on Fortinet, Raises Price Target to $95

LITE

Lumentum Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates.

<p>Barclays  analyst Gena Wang   maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Overweight and lowers the price target from $125 to $111.</p>


MRNA

Barclays Maintains Overweight on Moderna, Lowers Price Target to $111

<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%">
<p>On Thursday, <strong>Moderna Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported third-quarter revenue of $1.83 billion, beating the <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">consensus of $1.25 billion</a>.</p>
<p>The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.</p>
<p><strong>BofA Securities</strong> notes that Moderna&#8217;s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company&#8217;s respiratory vaccine lineup, as well as new concerns related to Trump and Kennedy&#8217;s positions on vaccines.</p>
<p>The analyst has reduced the <a href="https://www.benzinga.com/quote/MRNA/analyst-ratings">price target from $110 to $90</a>, adjusting for a higher discount rate (9% instead of 7%) based on updated commercial risk expectations, lower sales forecasts for COVID-19 and RSV vaccines, and reduced net cash. The analyst maintained a Neutral rating on Moderna.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology">Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology</a></strong></p>
<p><strong>Leerink Partners</strong> notes the earnings update didn&#8217;t improve the negative outlook for COVID and RSV, and the revenue beat, driven by excess inventory, pointed to weak earnings quality.</p>
<p>The company faces challenges from declining COVID demand and losing market share to <strong>Pfizer Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), which could affect Moderna's ability to clear excess inventory and raise concerns about potential write-downs in the fourth quarter of 2024.</p>
<p>Leerink has lowered the price target from $46 to $38, with an Underperform rating.</p>
<p><strong>Oppenheimer </strong>remains optimistic about the long-term potential of Moderna's RSV vaccine, mRESVIA growth. &#8220;We think MRNA is well-positioned to extend the mRESVIA label into high-risk adults 18-59, filing an sBLA with PRV by YE24,&#8221; the analyst writes, and maintains the Perform rating.</p>
<p>The analyst notes mRESVIA launch will take longer than expected but still considers it an undervalued asset, particularly with its upcoming label extension.</p>
<p>The analyst also adds, &#8220;We are impressed by MRNA&#8217;s progress toward opex optimization and believe such efficiency could invite a larger upside for its upcoming pipeline launches.&#8221;</p>
<p>The company expects the cost of sales to be 40-45% of product sales for the year (previously 40-50%), with R&amp;D expenses anticipated to be $4.6 billion—<a href="https://www.benzinga.com/calendars/guidance">$4.7 billion (previously $4.8 billion).</a></p>
<p><strong>Price Action: </strong>MRNA stock is down 6.33% at $47.10 at last check Friday.</p>
<p><em>Photo by Lutsenko_Oleksandr on Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report"><strong>Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</strong></a></li>
</ul>
</div>
</div>


Analyst Color

Biotech

Equities

Health Care

Reiteration

Trading Ideas

General

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Blackstone</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Blackstone.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 28%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $416,405, and 12 are calls, for a total amount of $768,583.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $185.0 for Blackstone, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Blackstone options trades today is 772.08 with a total volume of 1,075.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Blackstone's big money trades within a strike price range of $120.0 to $185.0 over the last 30 days.</p>
<h3>Blackstone Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091632_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.95</td>
<td>$7.7</td>
<td>$9.0</td>
<td>$130.00</td>
<td>$360.0K</td>
<td>7</td>
<td align="right">400</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.55</td>
<td>$7.95</td>
<td>$8.55</td>
<td>$170.00</td>
<td>$203.4K</td>
<td>1.6K</td>
<td align="right">239</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$140.00</td>
<td>$142.8K</td>
<td>958</td>
<td align="right">34</td>
</tr>
<tr>
<td>BX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$51.85</td>
<td>$47.7</td>
<td>$49.9</td>
<td>$145.00</td>
<td>$74.8K</td>
<td>174</td>
<td align="right">15</td>
</tr>
<tr>
<td>BX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$19.45</td>
<td>$18.85</td>
<td>$19.45</td>
<td>$185.00</td>
<td>$56.4K</td>
<td>0</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Blackstone</h3>
<p>Blackstone is the world's largest alternative-asset manager with $1.076 trillion in total asset under management, including $808.7 billion in fee-earning assets under management, at the end of June 2024. The company has four core business segments: private equity (25% of fee-earning AUM and 28% of base management fees), real estate (37% and 42%), credit and insurance (29% and 23%), and multi-asset investing (9% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).</p>
<p>In light of the recent options history for Blackstone, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Blackstone</h3>
<ul>
<li>With a trading volume of 1,086,978, the price of BX is up by 0.67%, reaching $177.48.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Blackstone</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $151.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Blackstone with a target price of $155.<br />
&#x2A; An analyst from TD Cowen has decided to maintain their Hold rating on Blackstone, which currently sits at a price target of $149.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Blackstone, which currently sits at a price target of $170.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Blackstone with a target price of $134.<br />
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Blackstone, maintaining a target price of $150. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Blackstone, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

A Closer Look at Blackstone's Options Market Dynamics

<p>Financial giants have made a conspicuous bullish move on Trade Desk. Our analysis of options history for Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) revealed 41 unusual trades.</p>
<p>Delving into the details, we found 46% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $587,459, and 29 were calls, valued at $2,049,304.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $148.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $50.0 to $148.0, over the past month.</p>
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091627_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.7</td>
<td>$15.1</td>
<td>$16.7</td>
<td>$140.00</td>
<td>$334.0K</td>
<td>1.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.7</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$140.00</td>
<td>$214.8K</td>
<td>1.0K</td>
<td align="right">428</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$19.55</td>
<td>$19.55</td>
<td>$19.55</td>
<td>$139.00</td>
<td>$146.6K</td>
<td>225</td>
<td align="right">75</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.1</td>
<td>$62.65</td>
<td>$64.1</td>
<td>$60.00</td>
<td>$128.2K</td>
<td>296</td>
<td align="right">76</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$66.35</td>
<td>$63.25</td>
<td>$64.5</td>
<td>$60.00</td>
<td>$103.2K</td>
<td>296</td>
<td align="right">46</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>Having examined the options trading patterns of Trade Desk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Trade Desk</h3>
<ul>
<li>With a volume of 10,134,362, the price of TTD is down -5.25% at $125.58. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $140.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Trade Desk, maintaining a target price of $150.<br />
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Overweight with a new price target of $150.<br />
&#x2A; An analyst from Wedbush persists with their Outperform rating on Trade Desk, maintaining a target price of $135.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Trade Desk, which currently sits at a price target of $135.<br />
&#x2A; Maintaining their stance, an analyst from Macquarie continues to hold a Outperform rating for Trade Desk, targeting a price of $130. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Trade Desk

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Redfin</strong>.</p>
<p>Looking at options history for Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) we detected 15 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $159,160 and 13, calls, for a total amount of $2,594,635.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $20.0 for Redfin over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Redfin's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Redfin's substantial trades, within a strike price spectrum from $5.0 to $20.0 over the preceding 30 days.</p>
<h3>Redfin Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731091622_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.0</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$8.00</td>
<td>$1.6M</td>
<td>1.7K</td>
<td>8.5K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.8</td>
<td>$5.0</td>
<td>$5.75</td>
<td>$5.00</td>
<td>$287.5K</td>
<td>7.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$4.3</td>
<td>$5.66</td>
<td>$5.00</td>
<td>$283.0K</td>
<td>7.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>RDFN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.85</td>
<td>$0.75</td>
<td>$0.75</td>
<td>$10.00</td>
<td>$120.1K</td>
<td>3.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RDFN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.25</td>
<td>$10.00</td>
<td>$113.7K</td>
<td>135</td>
<td>831</td>
</tr>
</tbody>
</table>
</p>
<h3>About Redfin</h3>
<p>Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.</p>
<p>After a thorough review of the options trading surrounding Redfin, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Redfin</h3>
<ul>
<li>With a volume of 13,061,904, the price of RDFN is down -16.84% at $9.53. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 109 days.</li>
</ul>
<h3>What Analysts Are Saying About Redfin</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $10.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush persists with their Neutral rating on Redfin, maintaining a target price of $10.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Redfin, targeting a price of $11. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Redfin with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


RDFN

Redfin's Options: A Look at What the Big Money is Thinking

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Outperform and raises the price target from $18 to $25.</p>


AAOI

Northland Capital Markets Maintains Outperform on Applied Optoelectronics, Raises Price Target to $25

PARA

Paramount Global shares are trading lower following mixed Q3 results.

<p>Northland Capital Markets  analyst Tim Savageaux   maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Market Perform and raises the price target from $45 to $60.</p>


Northland Capital Markets Maintains Market Perform on Lumentum Holdings, Raises Price Target to $60

<p>Northland Capital Markets  analyst Mike Grondahl   maintains MoneyLion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) with a Outperform and raises the price target from $60 to $80.</p>


Northland Capital Markets Maintains Outperform on MoneyLion, Raises Price Target to $80

<p>Northland Capital Markets  analyst Greg Gibas   maintains Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) with a Market Perform and lowers the price target from $3 to $2.</p>


NRDY

Northland Capital Markets Maintains Market Perform on Nerdy, Lowers Price Target to $2

<p>Northland Capital Markets  analyst Mike Grondahl   maintains Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform and raises the price target from $185 to $300.</p>


SEZL

Northland Capital Markets Maintains Outperform on Sezzle, Raises Price Target to $300

<p>U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.</p>
<p>Shares of <strong>Sony Group Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) rose sharply during Thursday's session after reporting better-than-expected second-quarter earnings and r<a href="https://www.benzinga.com/news/earnings/24/11/41841647/sonys-q2-profit-surges-on-gaming-and-sensor-gains-but-ps5-sales-decline-raises-full-year-outlook">aising FY24 revenue outlook</a>.</p>
<p>Sony Group reported fiscal second-quarter 2024 consolidated sales growth of 3% year-on-year to $19.44 billion (2.91 trillion Japanese yen), missing the analyst consensus estimate of $19.62 billion. EPS of $0.37 (55.74 yen) beat the analyst consensus estimate of $0.27.</p>
<p>Sony shares jumped 9.4% to $19.98 on Friday.</p>
<p>Here are some other big stocks recording gains in today's session.</p>
<ul>
<li><strong>Innodata Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares surged 67.7% to $40.84.</li>
<li><strong>Sezzle Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares jumped 51.7% to $380.00 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li><strong>Upstart Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) surged 44% to $79.89 after the company reported better-than-expected quarterly financial results.</li>
<li><strong>indie Semiconductor, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) gained 43.3% to $4.9200 after the company reported better-than-expected third-quarter financial results.</li>
<li><strong>Doximity, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 37.8% to $59.87 following better-than-expected second-quarter financial results.</li>
<li><strong>Fortrea Holdings Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) rose 32% to $23.82 after the company issued FY24 revenue guidance above estimates.</li>
<li><strong>Axon Enterprise, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) gained 26.3% to $591.89 after the company reported better-than-expected third-quarter financial results and issued current-quarter revenue guidance above estimates.</li>
<li><strong>Ubiquiti Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) gained 20.4% to $314.49 following upbeat quarterly earnings.</li>
<li><strong>Bloom Energy Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 19.8% to $12.78. The company announced a 20 MW utility deal with FPM Development and Baird maintained an Outperform rating on the stock.</li>
<li><strong>Tempus AI, Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NYSE">TEM</a>) gained 18.8% to $67.50.</li>
<li><strong>AAON, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) shares rose 15.7% to $137.83 after the company reported better-than-expected quarterly financial results. Also, Baird raised its price target on the stock from $130 to $138 and maintained an Outperform rating.</li>
<li><strong>Lumentum Holdings Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 14.4% to $84.25 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
<li><strong>Toast, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 13.3% to $37.00 after the company reported better-than-expected quarterly financial results.</li>
<li><strong>Tesla, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 8.3% to $321.66. The stock has continued to gain following the US presidential election.</li>
<li><strong>SharkNinja, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) gained 7.1% to $102.80.</li>
<li><strong>Expedia Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) gained 5.8% to $184.24 after the company reported better-than-expected third-quarter adjusted EPS results. </li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></strong></li>
</ul>


Intraday Update

Movers

AAON

AXON

DOCS

EXPE

FTRE

INDI

INOD

Sony Group Corporation American Depositary Shares

SONY

TOST

TSLA

UPST

Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday

<p>Northland Capital Markets  analyst Greg Gibas   maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Outperform and raises the price target from $16 to $37.</p>


Northland Capital Markets Maintains Outperform on GEO Group, Raises Price Target to $37

COIN

Coinbase shares are trading higher amid the election of President-Elect Trump as his policies could be favorable towards the crypto market.

Warning: CTMX is at high risk of performing badly

CytomX Q3 2024 Earnings Preview

Reports Q3 revenue $33.43M, consensus $17.61M. "We are encouraged by the progress during Q3 across our clinical pipeline including the ongoing Phas...

CytomX Therapeutics reports Q3 EPS 7c, consensus (17c)

CytomX Therapeutics Inc. ( ($CTMX) ) has released its Q3 earnings. Here is a breakdown of the information CytomX Therapeutics Inc. presented to its...

CytomX Therapeutics Reports Q3 Progress and Growth

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Piper Sandler lowered the firm's price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares follow...

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

CTMX

Opinion

Press Releases

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

Earnings

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BNTX

FGEN

ONCY

TSX:ONC

VSTM

Agenus

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bluebird bio

BeyondSpring

Celularity

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chimerix

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

IO Biotech

MAIA Biotechnology

Metagenomi

MediciNova

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Vistagen Therapeutics, Inc. - Common Stock

Comments

CytomX Therapeutics

Noticias

Últimas noticias sobre CytomX Therapeutics (NASDAQ:CTMX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL